Neurocrine Biosciences (NBIX) Current Assets (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Current Assets of $1.6 billion for Q2 2026, down 6.37% year-over-year from $1.7 billion in Q2 2025, and down 32.78% on a QoQ basis from $2.4 billion in Q1 2026.
Neurocrine Biosciences (NBIX) Current Assets (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Current Assets for 17 years, with the latest figure at $1.6 billion in Q2 2026.
- Current Assets for Q2 2026 came in at $1.6 billion, down 6.37% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.6 billion (down 6.37% YoY), and the FY2025 annual result was $2.5 billion, up 46.27% from the prior year.
- Current Assets retreated to $1.6 billion in Q2 2026, from $2.4 billion in the prior quarter.
- Over five years, Current Assets peaked at $2.5 billion in Q4 2025 and troughed at $1.0 billion in Q1 2022.
- A 5-year average of $1.7 billion and a median of $1.6 billion in 2023 frame the typical range for Current Assets.
- The widest annual swing landed in 2022, when Current Assets jumped 49.41%; it then retreated 8.95% in 2025.
- A 5-year view of Current Assets shows it stood at $1.5 billion in 2022, then grew by 10.56% to $1.6 billion in 2023, then advanced by 7.32% to $1.7 billion in 2024, then surged by 46.27% to $2.5 billion in 2025, then plunged by 35.09% to $1.6 billion in 2026.
- Per Business Quant data, the three most recent Current Assets figures were $1.6 billion in Q2 2026, $2.4 billion in Q1 2026, and $2.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 5.76 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 13.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 6.36 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 19.76 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 3.48 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 10.06 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.64 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.80 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 3.22 Bn |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 1.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.64 Bn |
| Mar 31, 2026 | 2.44 Bn |
| Dec 31, 2025 | 2.52 Bn |
| Sep 30, 2025 | 2.16 Bn |
| Jun 30, 2025 | 1.75 Bn |
| Mar 31, 2025 | 1.64 Bn |
| Dec 31, 2024 | 1.72 Bn |
| Sep 30, 2024 | 1.88 Bn |
| Jun 30, 2024 | 1.67 Bn |
| Mar 31, 2024 | 1.80 Bn |
| Dec 31, 2023 | 1.61 Bn |
| Sep 30, 2023 | 1.65 Bn |
| Jun 30, 2023 | 1.50 Bn |
| Mar 31, 2023 | 1.43 Bn |
| Dec 31, 2022 | 1.45 Bn |
| Sep 30, 2022 | 1.21 Bn |
| Jun 30, 2022 | 1.02 Bn |
| Mar 31, 2022 | 1.02 Bn |
| Dec 31, 2021 | 972.80 Mn |
| Sep 30, 2021 | 1.01 Bn |